Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Boehringer Ingelheim
Julphar
Cantor Fitzgerald
Mallinckrodt
Accenture
McKesson
Healthtrust

Generated: February 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FERROUS SULFATE; FOLIC ACID

« Back to Dashboard

Clinical Trials for Ferrous Sulfate; Folic Acid

Trial ID Title Status Sponsor Phase Summary
NCT00120822 Folic Acid Supplementation in Gambian Primigravidae Completed Department of State for Health and Social Welfare, The Gambia Phase 3 Supplementation with folic acid and iron is recommended for pregnant women in order to prevent them from developing anemia. In malaria endemic areas of Africa, the World Health Organization (WHO) now recommends that pregnant women should also be given sulfadoxine-pyrimethamine (SP) once a month after quickening to protect them against malaria which is especially harmful during pregnancy. However, folic acid is an antagonist of SP so there is a possibility that giving folic acid with SP could interfere with the ability of the latter to provide protection against malaria. To investigate this possibility Gambian primigravidae with malaria parasitemia have been given SP and folic acid at the same time or on separate occasions two weeks apart and the ability of SP to cure the malaria infection investigated.
NCT00120822 Folic Acid Supplementation in Gambian Primigravidae Completed London School of Hygiene and Tropical Medicine Phase 3 Supplementation with folic acid and iron is recommended for pregnant women in order to prevent them from developing anemia. In malaria endemic areas of Africa, the World Health Organization (WHO) now recommends that pregnant women should also be given sulfadoxine-pyrimethamine (SP) once a month after quickening to protect them against malaria which is especially harmful during pregnancy. However, folic acid is an antagonist of SP so there is a possibility that giving folic acid with SP could interfere with the ability of the latter to provide protection against malaria. To investigate this possibility Gambian primigravidae with malaria parasitemia have been given SP and folic acid at the same time or on separate occasions two weeks apart and the ability of SP to cure the malaria infection investigated.
NCT00120822 Folic Acid Supplementation in Gambian Primigravidae Completed Medical Research Council Unit, The Gambia Phase 3 Supplementation with folic acid and iron is recommended for pregnant women in order to prevent them from developing anemia. In malaria endemic areas of Africa, the World Health Organization (WHO) now recommends that pregnant women should also be given sulfadoxine-pyrimethamine (SP) once a month after quickening to protect them against malaria which is especially harmful during pregnancy. However, folic acid is an antagonist of SP so there is a possibility that giving folic acid with SP could interfere with the ability of the latter to provide protection against malaria. To investigate this possibility Gambian primigravidae with malaria parasitemia have been given SP and folic acid at the same time or on separate occasions two weeks apart and the ability of SP to cure the malaria infection investigated.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ferrous Sulfate; Folic Acid

Condition Name

Condition Name for Ferrous Sulfate; Folic Acid
Intervention Trials
Anemia 17
Iron Deficiency Anemia 13
Iron Deficiency 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ferrous Sulfate; Folic Acid
Intervention Trials
Anemia 28
Anemia, Iron-Deficiency 27
Deficiency Diseases 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ferrous Sulfate; Folic Acid

Trials by Country

Trials by Country for Ferrous Sulfate; Folic Acid
Location Trials
United States 86
Canada 2
Italy 2
Puerto Rico 2
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ferrous Sulfate; Folic Acid
Location Trials
Pennsylvania 7
Texas 7
Michigan 5
Ohio 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ferrous Sulfate; Folic Acid

Clinical Trial Phase

Clinical Trial Phase for Ferrous Sulfate; Folic Acid
Clinical Trial Phase Trials
Phase 4 9
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ferrous Sulfate; Folic Acid
Clinical Trial Phase Trials
Completed 25
Recruiting 10
Not yet recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ferrous Sulfate; Folic Acid

Sponsor Name

Sponsor Name for Ferrous Sulfate; Folic Acid
Sponsor Trials
Luitpold Pharmaceuticals 6
Watson Pharmaceuticals 4
AMAG Pharmaceuticals, Inc. 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ferrous Sulfate; Folic Acid
Sponsor Trials
Other 54
Industry 20
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Deloitte
Moodys
Chinese Patent Office
Colorcon
Johnson and Johnson
Boehringer Ingelheim
Julphar
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.